Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes.
Bosentan, a dual endothelin receptor blocker, has been used clinically to treat idiopathic pulmonary arterial hypertension (IPAH). However, the mechanism of its antiproliferative effect on pulmonary artery smooth muscle cells (PASMCs) remains unclear. A rise in cytoplasmic Ca2+ stimulates PASMC proliferation and the canonical transient receptor potential (TRPC) channels are an important pathway for Ca2+ entry during PASMC proliferation. Bosentan (20-50 microM) significantly inhibited endothelin-1- or platelet-derived growth factor (PDGF)-mediated PASMC growth and [3H]thymidine uptake. In PASMCs, endothelin-1 (1 microM) and PDGF (10 ng/ml) both upregulated protein expression of TRPC6, whereas bosentan markedly downregulated TRPC6 protein levels. Furthermore, TRPC6 expression in PASMCs from patients with IPAH was greater than in normal PASMCs, and the antiproliferative effect of bosentan was significantly enhanced in IPAH-PASMCs in comparison with normal PASMCs. These observations demonstrate that the antiproliferative effect of bosentan on PASMCs involves the downregulation of TRPC6 channels via a mechanism possibly independent of endothelin receptor blockade. The greater effect of bosentan on IPAH-PASMCs than on normal PASMCs suggests that increased TRPC6 expression and function may be involved in the overgrowth of PASMCs in patients with IPAH.
Department of Medicine, University of California, San Diego, La Jolla, California, USA.
Naomi
N
Kunichika
Judd W
JW
Landsberg
Ying
Y
Yu
Hideki
H
Kunichika
Patricia A
PA
Thistlethwaite
Lewis J
LJ
Rubin
Jason X-J
JX
Yuan
D000818:Animals; D015153:Blotting, Western; D000077300:Bosentan; D002121:Calcium Channel Blockers / Q000494:pharmacology; D015220:Calcium Channels / Q000187:drug effects / Q000378:metabolism*; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D019332:Endothelin-1 / Q000187:drug effects* / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D032389:Myocytes, Smooth Muscle / Q000187:drug effects*; D011651:Pulmonary Artery / Q000166:cytology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017466:Receptors, Endothelin / Q000187:drug effects* / Q000378:metabolism; D012016:Reference Values; D012494:Sampling Studies; D012680:Sensitivity and Specificity; D013449:Sulfonamides / Q000494:pharmacology*; D015854:Up-Regulation
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D019332:Endothelin-1; D017466:Receptors, Endothelin; D013449:Sulfonamides; D000077300:Bosentan